01/09/2026
Multiple myeloma accounts for approximately 10–15% of haematological malignancies, with Black populations disproportionately affected. This underscores the need for stronger diagnostic capacity, greater awareness and more accessible specialised testing.
At PathCare Kenya, we are proud to advance myeloma care by pioneering in-house Serum Free Light Chain testing, bringing this essential test closer to patients and supporting timely diagnosis, monitoring and informed clinical decision-making.
Dr. Rohini was among the PathCare Kenya team that participated in the Special Plasma Protein Workshop, hosted by The Binding Site and LABULAX SUPPLIES LIMITED. The team’s participation reflects our continued commitment to scientific collaboration, knowledge exchange and strengthening laboratory medicine across the region.
Because advancing patient care requires more than technology, it requires expertise, partnership and a shared commitment to better outcomes.